Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
about
A nonimmunosuppressant approach on Asia psoriasis subjects: 5-year followup and 11-year data analysisEffects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastCytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityUstekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primerThe emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsCirculating Th17, Th22, and Th1 cells are increased in psoriasisUstekinumabSelectivity and therapeutic inhibition of kinases: to be or not to be?Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesTargeting Th17 Cells with Small Molecules and Small Interference RNAA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisUstekinumab for the treatment of Crohn's disease: can it find its niche?Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPouring fuel on the fire: Th17 cells, the environment, and autoimmunityReview: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyondAdvances in the treatment of polyarticular juvenile idiopathic arthritisNew era of biologic therapeutics in atopic dermatitisJakpot! New small molecules in autoimmune and inflammatory diseasesBiologics in dermatology: an integrated reviewHydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeuticsInflammatory pathways of importance for management of inflammatory bowel diseaseInterleukin-23: as a drug target for autoimmune inflammatory diseasesPutting together the psoriasis puzzle: an update on developing targeted therapiesManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyNew targets in psoriatic arthritisTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabUstekinumab in Crohn's disease: evidence to date and place in therapyNovel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT)IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisApilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisPsoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalkIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Psoriasis and Atopic Dermatitis.
P2860
Q21296668-31006C97-902E-4E55-A72A-E3EF9DF66F38Q22299388-BC810066-25E3-4963-952A-39BC37EABC76Q22305855-C79CEC56-79B3-494D-AA48-F1C42AD44FB7Q22306446-AFB87F85-E7DD-4610-B712-001D3C5DDA1BQ24596756-CA973010-0C2A-4E51-A994-9115CB50EAEBQ24623195-6A373BE1-2DF2-42D4-8BE7-E3437E357DD6Q24629315-C6D4FEB9-620F-4CCD-B8B7-A9E2409D4B86Q24651927-C3701E96-8182-45C0-8447-77D7FB27128FQ24656006-FABF904C-0AF1-4E0A-BFBB-AD3049C80BC7Q26764820-1FF3A1E2-F23A-4269-BE3C-6138B4E9B00FQ26764867-BE5212AF-E24B-4789-8E9B-7D1BEF87AC50Q26770523-160790C7-B89E-49C3-9264-BFB2974D72A2Q26771682-D46D310C-814D-4416-AFA8-56E1E140DB6AQ26771890-CAB6C8A2-9306-438F-B297-1009A6E80E29Q26798209-7E2602AB-214A-4C22-B682-02F16233F3D8Q26822029-6752D88F-8A28-4AA6-B717-E93920028145Q26825174-98CA62FE-BE7F-4846-ADFA-F4214605598DQ26827714-5705D0A1-B719-4809-BC26-CA71F75B74F9Q26863295-DB544DA8-F6F4-45C5-83B8-D0A19E121F02Q26991709-2C1C8A47-98F3-495B-B20A-6E40521C036BQ27001017-B9D21AD8-1B63-44DE-B95D-A5218D8A76F7Q27001941-10476B49-9E83-4634-B1A7-642B2678C124Q27001957-BD824E66-618B-46B3-8B3C-0852FE0C2D1DQ27004638-E9C94D06-0C8D-40AD-92E6-637CE2E9BF99Q27004640-3908F766-300A-4B14-93D0-2A55995A87BCQ27005445-E455B56E-D90E-46EE-BAAE-8DAB45EEFB88Q27009502-D44C7C90-8432-4D3B-B4D3-DCC148992BD7Q27026785-13F1CBCD-B21A-497B-B21A-D7BABDF183C7Q27693878-9D3855B2-9DEE-4A27-B715-7210C1CB87A0Q28067631-00E99FCF-51A9-4F11-85D6-BC6A58A6DA47Q28069592-BEDB9B4D-23AD-4EDC-AD15-E41E11456D67Q28069819-DFAA8AA7-814D-41DC-9F19-E1C465F22DBAQ28073787-42FC7A70-F0FA-4BBC-B5E1-E8F534D4DEBEQ28081241-4D5678E8-D9B5-49B5-939A-79B64972B487Q28268370-9F76BCA4-19C8-448F-91B0-909C429F2B9BQ28280687-EBBAA4C9-2EEA-44E1-BE6F-1EF6CB8E0D27Q28482161-2D49B19A-81B8-49C9-A096-136E6CA1ED73Q28587108-DB542D15-F633-49AF-A90A-07FD192E4CAAQ30235581-E0FDE61A-E18E-491A-8395-65CEFCD7263BQ30238648-95087D7F-FC5B-4020-BCF6-77EB24F32B12
P2860
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@nl
type
label
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@nl
prefLabel
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@ast
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@en
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@nl
P2093
P921
P3181
P1433
P1476
Efficacy and safety of ustekin ...... o-controlled trial (PHOENIX 1)
@en
P2093
Craig L Leonardi
Cynthia Guzzo
Kenneth B Gordon
Kim A Papp
Lisa T Dooley
Newman Yeilding
PHOENIX 1 study investigators
Yuhua Wang
P304
P3181
P356
10.1016/S0140-6736(08)60725-4
P407
P577
2008-05-01T00:00:00Z